Headline Details

Spark's price for Luxturna blindness gene therapy too high: ICER

Published on: Fri, 12 Jan 2018 20:33:57 UTC
News Agency: Reuters
Description:
(Reuters) - The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

Click here for FULL Story on Reuters

Also happening now

HeadlineNews Agency
The diet to save lives, the planet and feed us all? BBC
U.S. considering allowing lawsuits over Cuba-confiscated properties Reuters
Powerful Tunisian union starts nationwide strike over pay Reuters
Football Leaks: 'Suspected hacker' detained in Hungary BBC
U.S. sees Palestinian state on most of West Bank, some of East Jerusalem: Israeli TV Reuters